Insurance Denial for Intravenous Immunoglobulin Therapy Effects Patients with Autoimmune Gastrointestinal Dysmotility
Title
Insurance Denial for Intravenous Immunoglobulin Therapy Effects Patients with Autoimmune Gastrointestinal Dysmotility
Creator
Edelbrock R; Owendoff G; Yan C; Wilson R
Publisher
Neurology
Date
2019
2019-04
Description
Objective: To identify the frequency of insurance related issues with intravenous immunoglobulin (IVIg) therapy approval for patients with autoimmune gastrointestinal dysmotility (AGID) and the outcomes of missed IVIg treatments.
Subject
Neurosciences & Neurology
Search for Full-text
Users with a NEOMED Library login can search for full-text journal articles at the following url: https://libraryguides.neomed.edu/home
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Pages
2-2
Issue
15
Volume
92
Citation
Edelbrock R; Owendoff G; Yan C; Wilson R, “Insurance Denial for Intravenous Immunoglobulin Therapy Effects Patients with Autoimmune Gastrointestinal Dysmotility,” NEOMED Bibliography Database, accessed May 10, 2024, https://neomed.omeka.net/items/show/6485.